Influenza A Virus Infection Clinical Trial
Official title:
Prospective Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents
The purpose of this study is to assess the serologic and cell-mediated immune response to licensed live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) in children 5-17 years old. The effects of prior infection and or prior season vaccination will be examined. Children will be followed during the influenza season to identify laboratory-confirmed influenza (i.e. vaccine failure).
All children will have baseline blood samples drawn and will then be vaccinated with licensed
and approved influenza vaccines. Following the recommendation from the Advisory Committee on
Immunization Practices, children 5-8 years old will preferentially receive live attenuated
influenza vaccine (LAIV). Children aged 9-17 will be randomized to receive either LAIV or
inactivated influenza vaccine (IIV). Children with a medical contraindication to any licensed
influenza vaccine will be excluded from the study.
The children will have their blood drawn between 2 and 4 times total over the course of two
months in order to test their immune response to the vaccine. Between approximately December
and April, study participants will be contacted weekly to monitor for any new respiratory
illnesses with cough, and if present, nasal and throat swabs will be collected to test for
influenza.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01175122 -
Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza
|
Phase 1 | |
| Completed |
NCT00984451 -
A Pilot Study for Collection of Anti-Influenza A Immune Plasma
|
||
| Completed |
NCT00985582 -
Antiviral Therapy for Influenza A H1N1
|
N/A | |
| Completed |
NCT01459081 -
Efficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China
|
Phase 3 | |
| Completed |
NCT03651544 -
The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac
|
Phase 1 | |
| Completed |
NCT02572817 -
Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A
|
Phase 3 | |
| Withdrawn |
NCT00844155 -
Study of the Relative Oral Bioavailability of the Antiflu Medicine Oseltamivir in the Intensive Care Unit
|
N/A | |
| Completed |
NCT00491985 -
Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children
|
Phase 2 | |
| Completed |
NCT01146535 -
Interferon Alpha Lozenges Plus Oseltamivir for Influenza Treatment
|
Phase 2 | |
| Completed |
NCT00457509 -
Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults
|
Phase 1 | |
| Completed |
NCT01546506 -
Confirmation of the Antiviral Effects of Midodrine Identified With a Gene Expression Signature-based Screening of Inluenza A Virus Infected Cells
|
Phase 2 | |
| Completed |
NCT01136057 -
Blood and Plasma Collection For Use in Future Clinical Trials
|